Genetics Variants and Serum Levels of MHC Class I Chain-related A in Predicting Hepatocellular Carcinoma Development in Chronic Hepatitis C Patients Post Antiviral Treatment
- PMID: 27998720
- PMCID: PMC5233818
- DOI: 10.1016/j.ebiom.2016.11.031
Genetics Variants and Serum Levels of MHC Class I Chain-related A in Predicting Hepatocellular Carcinoma Development in Chronic Hepatitis C Patients Post Antiviral Treatment
Erratum in
-
Corrigendum to "Genetics Variants and Serum Levels of MHC Class I Chain-related A in Predicting Hepatocellular Carcinoma Development in Chronic Hepatitis C Patients Post Antiviral Treatment" [EBioMedicine 15 (2017) 81-89].EBioMedicine. 2017 Mar;17:237. doi: 10.1016/j.ebiom.2017.02.027. Epub 2017 Mar 1. EBioMedicine. 2017. PMID: 28279639 Free PMC article. No abstract available.
Abstract
Background/aims: The genome-wide association study has shown that MHC class I chain-related A (MICA) genetic variants were associated with hepatitis C virus (HCV) related hepatocellular carcinoma (HCC). The impact of the genetic variants and its serum levels on post-treatment cohort is elusive [corrected].
Methods: MICA rs2596542 genotype and serum MICA (sMICA) levels were evaluated in 705 patients receiving antiviral therapy.
Results: Fifty-eight (8·2%) patients developed HCC, with a median follow-up period of 48·2 months (range: 6–129 months). The MICA A allele was associated with a significantly increased risk of HCC development in cirrhotic non-SVR patients but not in patients of non-cirrhotic and/or with SVR. For cirrhotic non-SVR patients, high sMICA levels (HR/CI: 5·93/1·86–26·38, P = 0·002) [corrected] and the MICA rs2596542 A allele (HR/CI: 4·37/1·52–12·07, P = 0·002) were independently associated with HCC development. The risk A allele or GG genotype with sMICA > 175 ng/mL provided the best accuracy (79%) and a negative predictive value of 100% in predicting HCC.
Conclusions: Cirrhotic patients who carry MICA risk alleles and those without risk alleles but with high sMICA levels possessed the highest risk of HCC development once they failed antiviral therapy.
Keywords: EGF; HCC; IL-28; MICA; PNPLA3; SNP; SVR; Treatment; sMICA.
Copyright © 2016 The Authors. Published by Elsevier B.V. All rights reserved.
Figures





References
-
- Asahina Y., Tsuchiya K., Nishimura T., Muraoka M., Suzuki Y., Tamaki N. Alpha-fetoprotein levels after interferon therapy and risk of hepatocarcinogenesis in chronic hepatitis C. Hepatology (Baltimore, Md) 2013;58(4):1253–1262. - PubMed
-
- Fabris C., Falleti E., Cussigh A., Bitetto D., Fontanini E., Bignulin S. IL-28B rs12979860 C/T allele distribution in patients with liver cirrhosis: role in the course of chronic viral hepatitis and the development of HCC. J. Hepatol. 2011;54(4):716–722. - PubMed
-
- Goto K., Kato N. MICA SNPs and the NKG2D system in virus-induced HCC. J. Gastroenterol. 2015;50(3):261–272. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials